1887

Chapter 25 : Suggested Future Research and Unanswered Questions

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Zoom in
Zoomout

Suggested Future Research and Unanswered Questions, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815684/9781555813734_Chap25-1.gif /docserver/preview/fulltext/10.1128/9781555815684/9781555813734_Chap25-2.gif

Abstract:

This section contains five parts. Part I talks about the host response and its implications; part II suggests research on the bacillus; part III suggests research on prophylactic vaccines and immunotherapy; part IV deals with development of new drugs for the treatment and prevention of tuberculosis; and part V provides sources of additional information. The cells participating in tuberculous lesions show a heterogeneity of functions, even among cells of identical appearance. The cytokines and cytokine receptors that are involved in the immune response within different organs should be identified by molecular biology techniques. Both DTH and CMI are mediated by Th1 lymphocytes and their cytokines. Tissue necrosis in clinical tuberculosis could be reduced by vaccines that cause little or no sensitivity to tuberculin. In rabbits, guinea pigs, and humans, microvascular thrombosis causes much of the tissue damage found in tuberculosis. Polymorphonuclear leukocytes (PMN) (neutrophils in humans, mice, and guinea pigs, but eosinophilic heterophils in rabbits) are common near solid and liquefied caseum. The prevention of clinical tuberculosis by a more effective vaccine than currently available BCG vaccines would be the most efficient way to reduce the incidence of this disease in the world. Immunotherapy should be pursued more extensively, because it would be of great benefit in treating multidrug-resistant tuberculosis, and because it could shorten the treatment of drug-susceptible tuberculosis.

Citation: Dannenberg, Jr. A. 2006. Suggested Future Research and Unanswered Questions, p 373-384. In Pathogenesis of Human Pulmonary Tuberculosis. ASM Press, Washington, DC. doi: 10.1128/9781555815684.ch25
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555815684.ch25
1. Nathan, C. 2002. Points of control in inflammation. Nature 420:846852.
2. Higuchi, S.,, M. Suga,, A. M. Dannenberg, Jr., and, B. H. Schofield. 1979. Histochemical demonstration of enzyme activities in plastic- and paraffin-embedded tissue sections. Stain Technol. 54:512.
3. Namba, M.,, A. M. Dannenberg, Jr., and, F. Tanaka. 1983. Improvement of the histochemical demonstration of acid phosphatase, β-galactosidase and nonspecific esterase in glycol methacry-late tissue sections by cold temperature embedding. Stain Technol. 58:207213.
4. Burstone, M. S. 1962. Enzyme Histochemistry and Its Application to the Study of Neoplasms, p. 863. Academic Press, Inc., New York, N.Y.
5. Lurie, M. B. 1964. Resistance to Tuberculosis: Experimental Studies in Native and Acquired Defensive Mechanisms. Harvard University Press, Cambridge, Mass.
6. Ando, M. 1973. Macrophage activation in tuber-culin reactions of rabbits with primary BCG infection and reinfection. J. Reticuloendothel. Soc. 14:132145.
7. Rees, R. J. W., and, P. D. Hart. 1961. Analysis of the host-parasite equilibrium in chronic murine tuberculosis by total and viable bacillary counts. Br. J. Exp. Pathol. 42:8388.
8. McKinney, J. D.,, K. Höner zu Bentrup,, E. J. Muñoz-Elias,, A. Miczak,, B. Chen,, W. T. Chan,, D. Svenson,, J. C. Sacchettini,, W. R. Jacobs, Jr., and, D. G. Russell. 2000. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 406:735738.
9. Long, E. R. 1958. The Chemistry and Chemotherapy of Tuberculosis. The Williams & Wilkins Co., Baltimore, Md.
10. Majno, G., and, I. Joris. 1996. Cells, Tissues, and Disease. Blackwell Science, Cambridge, Mass.
11. Kajiki, A.,, K. Higuchi,, M. Nakamura,, L. H. Liu,, P. J. Pula, and, A. M. Dannenberg, Jr. 1988. Sources of extracellular lysosomal enzymes released in organ culture by developing and healing inflammatory lesions. J. Leukoc. Biol. 43:104116.
12. Dannenberg, A. M., Jr.,, P. J. Pula,, L. Liu,, S. Harada,, F. Tanaka,, R. F. Vogt, Jr.,, A. Kajiki, and, K. Higuchi. 1985. Inflammatory mediators and modulators released in organ culture from rabbit skin lesions produced in vivo by sulfur mustard. I. Quantitative histopathology; PMN, basophil and mononuclear cell survival; and unbound (serum) protein content. Am. J. Pathol. 121:1527.
13. Brostoff, J.,, L. Lenzini,, P. Rottoli, and, L. Rottoli. 1981. Immune complexes in the spectrum of tuberculosis. Tubercle 62:169173.
14. Daniel, T. M. 1986. Circulating immune complexes in tuberculosis. Am. Rev. Respir. Dis. 134:199200. (Editorial.)
15. Doherty, T. M.,, A. Demissie,, J. Olobo,, D. Wolday,, S. Britton,, T. Eguale,, P. Ravn, and, P. Andersen. 2002. Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J. Clin. Microbiol. 40:704706.
16. Russell, D. G.,, G. E. Purdy,, R. M. Owens,, K. H. Rohde, and, R. M. Yates. 2005. Mycobacterium tuberculosis and the four-minute phagosome. ASM News 71:459463.
17. American Rabbit Breeders Association, Inc. 1996. Standard Bred Rabbits and Cavies, 1996 through 2000. American Rabbit Breeders Association, Inc., P. O. Box 426, Bloomington, IL 61702.
18. Smith, I. 2003. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Annu. Rev. Microbiol. 16:463496.
19. Zhang, Y. 2005. The magic bullets and tuberculosis drug targets. Annu. Rev. Pharmacol. Toxicol. 45:529564.
20. Zhang, Y. 2005. Persistent and dormant tubercle bacilli and latent tuberculosis. Front. Biosci. 9:11361156.
21. Russell, D. G. 2001. Mycobacterium tuberculosis: here today, and here tomorrow. Nat. Rev. Mol. Cell Biol. 2:569577.
22. Manabe, Y. C.,, A. M. Dannenberg, Jr.,, S. K. Tyagi,, C. L. Hatem,, M. Yoder,, S. C. Woolwine,, B. C. Zook,, M. L. M. Pitt, and, W. R. Bishai. 2003. Different strains of Mycobacterium tuberculosis cause various spectrums of disease in the rabbit model of tuberculosis. Infect. Immun. 71:60046011.
23. Constant, P.,, E. Perez,, W. Malaga,, M. A. Lanéelle,, O. Saurel,, M. Daffé, and, C. Guilhot. 2002. Role of the pks15/1 gene in the biosynthesis of phenolglycolipids in the Mycobacterium tuberculosis complex. Evidence that all strains synthesize glycosylated p-hydroxybenzoic methyl esters and that strains devoid of phenolglycolipids harbor a frameshift mutation in the pks15/1 gene. J. Biol. Chem. 277:3814838158.
24. Steyn, A. J. C.,, D. M. Collins,, M. K. Hondalus,, W. R. Jacobs, Jr.,, R. P. Kawakami, and, B. R. Bloom. 2002. Mycobacterium tuberculosis WhiB3 interacts with RpoV (which is Sig A) to affect host survival but is dispensable for in vivo growth. Proc. Natl. Acad. Sci. USA 99:31473152.
25. Francis, J. 1958. Tuberculosis in Animals and Man. A Study in Comparative Pathology. Cassell and Co., London, United Kingdom.
26. Dannenberg, A. M., Jr. 1984. Pathogenesis of tuberculosis: native and acquired resistance in animals and humans, p. 344354. In D. Schlessinger (ed.), Microbiology—1984. American Society for Microbiology, Washington, D.C.
27. Lurie, M. B., and, A. M. Dannenberg, Jr. 1965. Macrophage function in infectious disease with inbred rabbits. Bacteriol. Rev. 29:466476.
28. Comstock, G. W. 1994. Field trials of tuberculosis vaccines: how could we have done them better? Control. Clin. Trials 15:247276.
29. Stanford, J.,, C. Stanford, and, J. C. Grange. 2004. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis. Front. Biosci. 9:17011719.
30. Walsh, C. 2003. Antibiotics: Actions, Origins, Resistance. ASM Press, Washington, D.C.
31. O’Brien, R. J., and, P. P. Nunn. 2001. The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps. Am. J. Respir. Crit. Care Med. 162:10551058.
32. Grosset, J. 2003. Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary. Antimicrob. Agents Chemother. 47:833836.
33. Gomez, J. E., and, J. D. McKinney. 2004. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis 84:2944.
34. Adams, L. B.,, I. Sinha,, S. G. Franzblau, and, J. L. Krahenbuhl. 1999. Effective treatment of acute and chronic murine tuberculosis with lipo-some-encapsulated clofazimine. Antimicrob. Agents Chemother. 43:16381643.
35. Daniel, J.,, C. Deb,, V. S. Dubey,, T. D. Sirakova,, B. Abomoelak,, H. R. Morbidoni, and, P. E. Kolattukudy. 2004. Induction of a novel class of diacylglycerol acyltransferase and triglycerol accumulation in Mycobacterium tuberculosis as it goes into a dormancy-like state in culture. J. Bacteriol. 186:50175030.
36. Cole, S. T., and, P. M. Alzari. 2005. Perspectives: TB—a new target drug. Science 307:214215.
37. Andries, K.,, P. Verhasselt,, J. Guillemont,, H. W. H. Göhlmann,, J.-M. Neefs,, H. Winkler,, J. van Gestel,, P. Timmerman,, M. Zhu,, E. Lee,, P. Williams,, D. de Chaffoy,, E. Huitric,, S. Hoffner,, E. Cambau,, C. Truffot-Pernot,, N. Lounis, and, V. Jarlier. 2005. A diarylquinoline drug active on ATP synthase of Mycobacterium tuberculosis. Science 307:223227.
38. Zhang, Y.,, K. Post-Martens, and, S. Denkin. 2006. New drug candidates and therapeutic targets for tuberculosis therapy. Drug Discov. Today 11:2127.
39. Stover, C. K.,, P. Warrener,, D. R. VanDevanter,, D. R. Sherman,, T. M. Arain,, M. H. Lang-horne,, S. W. Anderson,, J. A. Towell,, Y. Yuan,, D. N. McMurray,, B. N. Kreiswirth,, C. E. Barry, and, W. R. Baker. 2000. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405:962966.
40. Tyagi, S.,, E. Nuermberger,, T. Yoshimatsu,, K. Williams,, I. Rosenthal,, N. Lounis,, W. Bishai, and, J. Grosset. 2005. Bactericidal activity of the nitroimidazopyran, PA-824, in the murine model of tuberculosis. Antimicrob. Agents Chemother. 49:22892293.
41. Nuermberger, E. L.,, T. Yoshimatsu,, S. Tyagi,, R. J. O’Brien,, A. N. Vernon,, R. E. Chaisson,, W. R. Bishai, and, J. H. Grosset. 2004. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am. J. Respir. Crit. Care Med. 169:421426.
42. Nuermberger, E. L.,, T. Yoshimatsu,, S. Tyagi,, K. Williams,, I. Rosenthal,, R. J. O’Brien,, A. A. Vernon,, R. E. Chaisson,, W. R. Bishai, and, J. H. Grosset. 2004. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am. J. Respir. Crit. Care Med. 170:11311134.
43. Valerio, G.,, P. Bracciale,, V. Manisco,, M. Quitadamo,, G. Legari, and, S. Bellanova. 2003. Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. J. Chemother. 15:6670.
44. Cole, S. T.,, K. D. Eisenach,, D. N. McMurray, and, W. R. Jacobs, Jr. (ed.). 2005. Tuberculosis and the Tubercle Bacillus. ASM Press, Washington, D.C.
45. Cole, S. T. 2002. Comparative and functional genomics of the Mycobacterium tuberculosis complex. Microbiology 148:2919-2928.
46. Wade, M. M., and, Y. Zhang. 2004. Mechanisms of drug resistance in Mycobacterium tuberculosis. Front. Biosci. 9:975994.
47. American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Disease Society of America. 2003. Official joint statement for the treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603662.
48. Centers for Disease Control and Prevention. 2005. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. Morb. Mortal. Wkly. Rep. 54(RR-17):1141.

Tables

Generic image for table
TABLE 1

In vivo effectiveness of principal antituberculous agents on tubercle bacilli in various metabolic states a

Citation: Dannenberg, Jr. A. 2006. Suggested Future Research and Unanswered Questions, p 373-384. In Pathogenesis of Human Pulmonary Tuberculosis. ASM Press, Washington, DC. doi: 10.1128/9781555815684.ch25

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error